Empowering the MDS Community
Patient & Visitor
Explore comprehensive resources tailored for patients and their loved ones. Understand your diagnosis, access treatment information, and find support in every step of your journey. We're here to provide clarity, comfort, and a sense of community.
Who is the MDS Foundation?
We are a global non-profit advocacy organization building critical awareness of Myelodysplastic Syndromes (MDS) - a rare, often undetected blood cancer. The MDS Foundation has supported patients and their families as well as healthcare providers in the fields of MDS, AML and other related cancers for over 30 years.
The MDS FoundationWhat is MDS?
Myelodysplastic syndromes (MDS) are a group of bone marrow failure disorders. Healthy bone marrow produces immature blood cells — stem cells - that normally develop into mature, fully functional red blood cells, white blood cells, and platelets. In MDS, these stem cells may not mature and may accumulate in the bone marrow or they may have a shortened life span, resulting in fewer than normal mature blood cells in the circulation.
Learn MoreHealthy Blood
Blood Cancer
Upcoming Events
MDS Nutrition: Fueling Your Body For Strength
MDS Nutrition: Fueling Your Body For Strength
February 4, 2025
What's New?
December 18, 2024
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Syndax Pharmaceuticals (Nasdaq: SNDX) announced that the FDA has approved Revuforj® (revumenib) for treating relapsed or refractory acute leukemia with KMT2A translocation in adults and pediatric patients aged one and older. Approved based on positive results from the AUGMENT-101 trial, Revuforj is the first and only menin inhibitor for this indication. Syndax plans to launch the drug this month and will host a conference call today at 6:00 p.m. ET to discuss the approval.
Join Our Mailing List
Stay informed and supported. Join our mailing list today for the latest updates, resources, and community events delivered directly to your inbox.
Materials Spotlight
Testimonials
The MDS Foundation has been a great resource for our patients. We held a successful local symposium last year and hope to do that again in the future.
Afaf O
MDSF is fantastic so glad to have you there.
Amy D
We have enjoyed working with the MDS Foundation for many years.
Richard L
MDSF is a terrific organisation, and we appreciate the relationship.
Daniel P
I refer people regularly to the website and patient support services. The MDS Foundation is a great resource.
Mark J
I and my patients are huge fans of the MDS Foundation!
Yazan M
We are excited to keep working with the MDS Foundation as an MDS Center of Excellence to provide our patients the highest quality and state of the art care.
Aditi S
I believe that the Understanding Your MDS booklets and Building Blocks of Hope, MDS and AML Editions are invaluable resources, and I would love to be able to give them to my newly diagnosed patients.
Sophia B
My overall experience with the MDS Foundation is excellent.
Suresh D
I reviewed information on the MDS Foundation website in various languages, and it is very impressive.
Suresh D
It has been a tremendous blessing to have the MDS Foundation’s Northwestern team helping us through our MDS journey.
Stephen and Pat F
Center of excellence is like a 4 star Michelin restaurant rating.
Robert S
The MDS Foundation can assist you in getting into a center of excellence for MDS quickly. It is a top priority.
Amy C
I have found the forum to be a great help.
Marjory B
In my opinion everyone with MDS should put their trust in center of excellence.
Michael